ticlopidine has been researched along with Transfusion Reaction in 4 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Transfusion Reaction: Complications of BLOOD TRANSFUSION. Included adverse reactions are common allergic and febrile reactions; hemolytic (delayed and acute) reactions; and other non-hemolytic adverse reactions such as infections and adverse immune reactions related to immunocompatibility.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral reversible platelet P2Y12 receptor inhibitors (ticagrelor and elinogrel) cause double-digit rates of dyspnea, while irreversible oral antiplatelet drugs (aspirin, ticlopidoine, clopidogrel, and prasugrel) or intravenous glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, or tirofiban) do not increase the incidence of dyspnea in randomized trials." | 8.90 | Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond. ( DiNicolantonio, JJ; Serebruany, VL; Sibbing, D, 2014) |
| "Oral reversible platelet P2Y12 receptor inhibitors (ticagrelor and elinogrel) cause double-digit rates of dyspnea, while irreversible oral antiplatelet drugs (aspirin, ticlopidoine, clopidogrel, and prasugrel) or intravenous glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, or tirofiban) do not increase the incidence of dyspnea in randomized trials." | 4.90 | Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond. ( DiNicolantonio, JJ; Serebruany, VL; Sibbing, D, 2014) |
| "We performed a retrospective cohort study of 1677 patients undergoing coronary artery bypass surgery to determine the relationship of the preoperative use of aspirin plus clopidogrel vs aspirin alone to the 30-day incidence of postoperative surgical site infection and bacteremia." | 3.75 | Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery. ( Alejo, D; Baumgartner, WA; Blasco-Colmenares, E; Conte, JV; Faraday, N; Guallar, E; Pastor-Barriuso, R; Perl, TM; Sharrett, AR, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rosengart, TK | 1 |
| Romeiser, JL | 1 |
| White, LJ | 1 |
| Fratello, A | 1 |
| Fallon, E | 1 |
| Senzel, L | 1 |
| Shroyer, AL | 1 |
| Serebruany, VL | 1 |
| Sibbing, D | 1 |
| DiNicolantonio, JJ | 1 |
| Jones, DW | 1 |
| Schermerhorn, ML | 1 |
| Brooke, BS | 1 |
| Conrad, MF | 1 |
| Goodney, PP | 1 |
| Wyers, MC | 1 |
| Stone, DH | 1 |
| Blasco-Colmenares, E | 1 |
| Perl, TM | 1 |
| Guallar, E | 1 |
| Baumgartner, WA | 1 |
| Conte, JV | 1 |
| Alejo, D | 1 |
| Pastor-Barriuso, R | 1 |
| Sharrett, AR | 1 |
| Faraday, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Alignment of Treatment Preferences and Repair Type for Veterans With AAA[NCT03115346] | 238 participants (Anticipated) | Interventional | 2017-04-15 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ticlopidine and Transfusion Reaction
| Article | Year |
|---|---|
Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.
Topics: Acute Lung Injury; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Dyspnea; H | 2014 |
3 other studies available for ticlopidine and Transfusion Reaction
| Article | Year |
|---|---|
Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration.
Topics: Aged; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass; Decision Suppor | 2013 |
Perioperative clopidogrel is associated with increased bleeding and blood transfusion at the time of lower extremity bypass.
Topics: Aged; Blood Loss, Surgical; Blood Transfusion; Chi-Square Distribution; Clopidogrel; Databases, Fact | 2017 |
Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery.
Topics: Aged; Aspirin; Bacteremia; Blood Transfusion; Clopidogrel; Cohort Studies; Coronary Artery Bypass; D | 2009 |